{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:50:30Z","timestamp":1790740230267,"version":"4.1.0"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To highlight recent findings on the adequate duration of antifungal therapy in patients with invasive fungal disease (IFD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Plenty of published data available suggest that there is no additional clinical benefit at a certain point after initiation of antifungal treatment in patients with confirmed IFD. Moreover, the prolonged antifungal exposure can be associated with an increased risk of side effects and toxicity as well as striking risk for developing antifungal resistance or rising unnecessary healthcare costs. Recent data suggest that, in the presence of an adequate initial antifungal therapy and adequate source control of the infection, new stratified approaches integrating clinical judgment, biomarkers and microbiological eradication, should be considered as an alternative to the \u2018one-size-fits-all\u2019 treatment duration currently used worldwide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The optimal duration of antifungal therapy is still an unresolved issue that depends by many key elements including the host; the pathogen and its microbiological eradication, the adequateness of initial antifungal therapy and the promptness of source control of the infection. In general, many patients with invasive candidiasis can be treated with a 2 weeks course of antifungal therapy. Longer antifungal course (6 weeks or more) is generally required for patients with invasive aspergilosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000000758","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T19:07:27Z","timestamp":1607972847000},"page":"466-472","source":"Crossref","is-referenced-by-count":6,"title":["Adequate duration of therapy in severe fungal infections"],"prefix":"10.1097","volume":"26","author":[{"given":"Matteo","family":"Bassetti","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele R.","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Berruti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Del Puente","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-13-29","article-title":"Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes","volume":"13","author":"Baddley","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R2-20230913","doi-asserted-by":"crossref","first-page":"105992","DOI":"10.1016\/j.ijantimicag.2020.105992","article-title":"Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: a multicentre observational study by the Turkish Fungal Infections Study Group","author":"Dogan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/ciu158","article-title":"Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis","volume":"58","author":"Fernandez-Ruiz","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","article-title":"A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality","volume":"40","author":"Bassetti","year":"2014","journal-title":"Intensive Care Med"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s10096-018-3335-2","article-title":"Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship","volume":"37","author":"Valerio","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R6-20230913","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","author":"Gomez-Lopez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40121-020-00282-w","article-title":"Comparison of the safety and tolerance profile of micafungin with that of other echinocandins and azoles in patients with preexisting child-pugh B or C liver disease: a case-control retrospective study","volume":"9","author":"Vena","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"(Suppl 2)","key":"R8-20230913","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/myc.12332","article-title":"Advances in the management of fungal infections","volume":"58","author":"Munoz","year":"2015","journal-title":"Mycoses"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/jac\/dku053","article-title":"Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed","volume":"69","author":"Valerio","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R11-20230913","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1093\/jac\/dkv241","article-title":"Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment","volume":"70","author":"Martinez-Jimenez","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R12-20230913","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"R14-20230913","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.02.017","article-title":"Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?","author":"Bassetti","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cmi.2018.01.022","article-title":"Is biofilm production a prognostic marker in adults with candidaemia?","volume":"24","author":"Munoz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/23744235.2017.1384956","article-title":"The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data","volume":"50","author":"Tascini","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13054-020-2793-y","article-title":"Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts","volume":"24","author":"Bassetti","year":"2020","journal-title":"Crit Care"},{"key":"R18-20230913","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40121-020-00280-y","article-title":"Therapeutic drug monitoring of antifungal drugs: another tool to improve patient outcome?","volume":"9","author":"Vena","year":"2020","journal-title":"Infect Dis Ther"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1055\/s-0039-1693704","article-title":"Diagnosis and treatment of candidemia in the intensive care unit","volume":"40","author":"Bassetti","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00268-004-7505-2","article-title":"Source control for surgical infections","volume":"28","author":"Schein","year":"2004","journal-title":"World J Surg"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/CCM.0000000000002011","article-title":"Impact of source control in patients with severe sepsis and septic shock","volume":"45","author":"Martinez","year":"2017","journal-title":"Crit Care Med"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/653935","article-title":"Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials","volume":"51","author":"Nucci","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R25-20230913","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10096-019-03477-3","article-title":"Persistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era","volume":"38","author":"Agnelli","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","article-title":"ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients","volume":"45","author":"Martin-Loeches","year":"2019","journal-title":"Intensive Care Med"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"R28-20230913","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R29-20230913","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: a randomised noninferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"R30-20230913","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"R31-20230913","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s00134-013-3109-3","article-title":"A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts","volume":"39","author":"Bassetti","year":"2013","journal-title":"Intensive Care Med"},{"key":"R32-20230913","first-page":"1578","article-title":"Short-course antimicrobial therapy for intraabdominal infection","volume":"373","author":"Guidry","year":"2015","journal-title":"N Engl J Med"},{"key":"R33-20230913","first-page":"870","article-title":"Ultra-short-course antibiotics for patients with suspected ventilator-associated pneumonia but minimal and stable ventilator settings","volume":"64","author":"Klompas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R34-20230913","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/cid\/ciz223","article-title":"Antibiotic therapy for pseudomonas aeruginosa bloodstream infections: how long is long enough?","volume":"69","author":"Fabre","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1086\/313499","article-title":"A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B","volume":"29","author":"Fichtenbaum","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R36-20230913","doi-asserted-by":"crossref","first-page":"1","DOI":"10.37201\/req\/2260.2019","article-title":"Biomarkers of fungal infection: expert opinion on the current situation","volume":"33","author":"Bouza","year":"2020","journal-title":"Rev Esp Quimioter"},{"key":"R37-20230913","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/cid\/ciz555","article-title":"Clinical relevance and prognostic value of persistently negative (1,3)-beta-d-glucan in adults with candidemia: a 5-year experience in a tertiary hospital","volume":"70","author":"Agnelli","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"(Suppl_4)","key":"R38-20230913","doi-asserted-by":"crossref","first-page":"iv13","DOI":"10.1093\/jac\/dky048","article-title":"T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study","volume":"73","author":"Munoz","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R39-20230913","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R40-20230913","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"R41-20230913","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, noninferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"issue":"(Suppl 1)","key":"R42-20230913","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R43-20230913","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"R44-20230913","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/crj.12551","article-title":"Values of radiological examinations for the diagnosis and prognosis of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary diseases","volume":"12","author":"Huang","year":"2018","journal-title":"Clin Respir J"},{"key":"R45-20230913","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jinf.2020.03.065","article-title":"Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis","volume":"81","author":"Bassetti","year":"2020","journal-title":"J Infect"},{"key":"R46-20230913","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fmicb.2018.00661","article-title":"Galactomannan, a surrogate marker for outcome in invasive aspergillosis: finally coming of age","volume":"9","author":"Mercier","year":"2018","journal-title":"Front Microbiol"},{"key":"R47-20230913","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/13693780801978968","article-title":"Value of a single galactomannan determination (Platelia) for the diagnosis of invasive aspergillosis in nonhematological patients with clinical isolation of Aspergillus spp","volume":"46","author":"Guinea","year":"2008","journal-title":"Med Mycol"},{"key":"R48-20230913","first-page":"148","article-title":"Assessment of Platelia Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis","volume":"40","author":"Lai","year":"2007","journal-title":"J Microbiol Immunol Infect"},{"key":"R49-20230913","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","article-title":"Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients","volume":"177","author":"Meersseman","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R50-20230913","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jinf.2010.08.014","article-title":"Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis","volume":"61","author":"Park","year":"2010","journal-title":"J Infect"},{"key":"R51-20230913","first-page":"1","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion","volume":"22","author":"Verweij","year":"2020","journal-title":"Intensive Care Med"},{"key":"R52-20230913","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive Care Med"},{"key":"R53-20230913","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1469-0691.2010.03357.x","article-title":"A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1\u200a-->\u200a3)-beta-d-glucan chromogenic assay in serum samples","volume":"17","author":"Acosta","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R54-20230913","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jinf.2016.02.019","article-title":"Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in nonhematological patients","volume":"72","author":"Fortun","year":"2016","journal-title":"J Infect"},{"key":"R55-20230913","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/cc11443","article-title":"Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study","volume":"16","author":"He","year":"2012","journal-title":"Crit Care"},{"key":"R56-20230913","doi-asserted-by":"crossref","first-page":"12","DOI":"10.18869\/acadpub.cmm.1.1.12","article-title":"Detection of galactomannan in bronchoalveolar lavage of the intensive care unit patients at risk for invasive aspergillosis","volume":"1","author":"Khodavaisy","year":"2015","journal-title":"Curr Med Mycol"},{"key":"R57-20230913","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.201407-1275OC","article-title":"Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases","volume":"190","author":"Prattes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R58-20230913","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1128\/JCM.05026-11","article-title":"Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay","volume":"49","author":"Torelli","year":"2011","journal-title":"J Clin Microbiol"},{"key":"R59-20230913","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"R60-20230913","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc4823","article-title":"Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients","volume":"10","author":"Vandewoude","year":"2006","journal-title":"Crit Care"},{"key":"R61-20230913","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the Mycoses Study Group Education and Research Consortium","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R62-20230913","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/myc.12869","article-title":"Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project","volume":"62","author":"Bassetti","year":"2019","journal-title":"Mycoses"},{"key":"R63-20230913","doi-asserted-by":"crossref","first-page":"e1040","DOI":"10.1016\/j.ijid.2010.08.005","article-title":"Aspergillus endocarditis: a review of the literature","volume":"14","author":"Kalokhe","year":"2010","journal-title":"Int J Infect Dis"},{"key":"R64-20230913","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/mmy\/myw043","article-title":"Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis","volume":"54","author":"Zhao","year":"2016","journal-title":"Med Mycol"},{"key":"R65-20230913","doi-asserted-by":"crossref","first-page":"562e1","DOI":"10.1016\/j.cmi.2016.01.027","article-title":"Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients","volume":"22","author":"Imbert","year":"2016","journal-title":"Clin Microbiol Infect"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:21:04Z","timestamp":1694632864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000000758","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]}}}